Form 8-K - Current report:
SEC Accession No. 0001213900-25-107180
Filing Date
2025-11-06
Accepted
2025-11-06 16:24:36
Documents
14
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0264261-8k_nektar.htm   iXBRL 8-K 25010
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL R ea026426101ex99-1_nektar.htm EX-99.1 83138
3 GRAPHIC ex99-1_001.jpg GRAPHIC 17670
  Complete submission text file 0001213900-25-107180.txt   309075

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20251106.xsd EX-101.SCH 3008
5 XBRL LABEL FILE nktr-20251106_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE nktr-20251106_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0264261-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251458768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)